Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A

V R Babaev1, L A Gleaves, K J Carter

  • 1Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-6300, USA.

Insights

Mice lacking scavenger receptor A (SR-A)-I/II showed significantly reduced atherosclerosis. Macrophage SR-A-I/II expression critically drives atherosclerotic lesion development, independent of plasma lipid levels.

Area of Science:

  • Immunology
  • Cardiovascular Biology
  • Molecular Medicine

Background:

  • Scavenger receptor A (SR-A)-I/II absence yields variable atherosclerosis outcomes in murine models.
  • C57BL/6 mice are susceptible to diet-induced atherosclerosis.
  • LDL receptor (LDLR)(-/-) mice are commonly used models for atherosclerosis research.

Purpose of the Study:

  • To investigate the impact of SR-AI/II deficiency on diet-induced atherogenesis in C57BL/6 mice.
  • To determine if macrophage-specific SR-AI/II expression influences lesion development in C57BL/6 and LDLR(-/-) mice.

Main Methods:

  • SR-AI/II-deficient (SR-AI/II(-/-)) and wild-type (SR-AI/II(+/+)) mice on C57BL/6 background were fed a butterfat diet.
  • Bone marrow transplantation models using SR-AI/II(-/-) or SR-AI/II(+/+) fetal liver cells into C57BL/6 and LDLR(-/-) recipients were established.
  • Plasma lipids, lipoprotein profiles, and atherosclerotic lesion areas were analyzed.

Main Results:

  • SR-AI/II(-/-) mice exhibited 81-86% reduction in aortic lesion area compared to SR-AI/II(+/+) mice, with no plasma lipid differences.
  • Mice reconstituted with SR-AI/II(-/-) fetal liver cells showed a 60% reduction in aortic lesion area compared to controls in both C57BL/6 and LDLR(-/-) models.
  • No significant differences in plasma lipids or lipoproteins were observed between experimental and control groups.

Conclusions:

  • Macrophage SR-AI/II expression is a significant contributor to atherosclerotic lesion formation.
  • SR-AI/II deficiency does not affect plasma lipid levels.
  • Targeting macrophage SR-AI/II may represent a therapeutic strategy for atherosclerosis.

Related Concept Videos